|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2011
|
|
gptkbp:ATCCode
|
L01XC12
|
|
gptkbp:blackBoxWarning
|
gptkb:progressive_multifocal_leukoencephalopathy
|
|
gptkbp:brand
|
gptkb:Adcetris
|
|
gptkbp:CASNumber
|
914088-09-8
|
|
gptkbp:category
|
immunotherapy
oncology drug
|
|
gptkbp:contains
|
gptkb:monomethyl_auristatin_E
|
|
gptkbp:contraindication
|
concurrent use with bleomycin
hypersensitivity to brentuximab vedotin
|
|
gptkbp:developedBy
|
gptkb:Seattle_Genetics
gptkb:Millennium_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
4 to 6 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
brentuximab vedotin
|
|
gptkbp:indication
|
gptkb:mycosis_fungoides
gptkb:primary_cutaneous_anaplastic_large_cell_lymphoma
leukemia
relapsed or refractory systemic anaplastic large cell lymphoma
relapsed or refractory Hodgkin lymphoma
|
|
gptkbp:KEGGID
|
D09713
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
CD30-positive cells
|
|
gptkbp:mechanismOfAction
|
inhibits microtubule polymerization
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:proteinBinding
|
high
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1743027
none
117396537
DB05852
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
diarrhea
fatigue
peripheral neuropathy
neutropenia
thrombocytopenia
|
|
gptkbp:target
|
gptkb:CD30
|
|
gptkbp:UNII
|
3ZJ8QYF7F5
|
|
gptkbp:usedFor
|
Hodgkin lymphoma
systemic anaplastic large cell lymphoma
|
|
gptkbp:bfsParent
|
gptkb:Adcetris
|
|
gptkbp:bfsLayer
|
6
|